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Clinical ratings scalePlant food supplements (PFS) have become increasingly popular with respect to their con-
sumption for improving human immune function. Despite this popularity, critical review is
lacking regarding the analytical methods used to assess PFS outcome. The suitability of
such methods for clinical-based studies remains particularly unclear. We undertook a liter-
ature-based review of the methods used to assess PFS outcome in immune function, to
identify and assess the relevance of different technologies. Most methods described in this
review adequately measured the functions of innate and adaptive immunity, were applica-
ble to both healthy and diseased subjects, and were appropriate for assessing the benefit
claims of PFS on immune function. However, the design and reporting quality of studies
varied widely across trials, in some cases potentially impacting negatively on the outcomes
and interpretations. Several strategies to enhance study robustness and quality were out-
lined, to improve the validity of the data generated in the field.
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The human immune system is comprised of networks of
cells, tissues, and organs, which together represent the body’s
primary mechanism for preventing diseases that arise
through toxins or infection from pathogenic microorganisms’
including bacteria, viruses and fungi (Parham, 2009). To pre-
vent or overcome infection the immune system is therefore
required to function fast and effective against a range of
pathogens, often under varying environmental (e.g. seasonal
changes) or physiological (e.g. stress) conditions. The func-
tions of the immune system are categorised into two major
components, innate response and adaptive response, each
of which is classified according to the speed and specificity
of the immune reaction. Innate immunity encompasses cellu-
lar elements such as neutrophils, monocytes, macrophages,
cytokines, and serum complement proteins, which provide
immediate sensing and host defence against pathogens
(Bonilla & Oettgen, 2010). These elements rely on recognising
the presence of pathogens or their products through the ini-
tial binding of soluble proteins and cell-surface receptors
which then facilitate the process of elimination (Bonilla &
Oettgen, 2010; Parham, 2009). At the same time humoral ele-
ments also contribute significantly, in particular antimicro-
bial peptides such as defensins, glycoproteins and
proteoglycans. In addition, the body is host to symbiotic com-
munities of benign microbial flora that prevent infection by
colonising tracts, and producing antimicrobial proteins such
as colicins that incapacitate other bacteria (Di Meglio, Perera,
& Nestle, 2011; Parham, 2009; Turvey & Broide, 2010).
In contrast, adaptive immunity results from antigen-
specific reactions facilitated through T and B lymphocytes in
two main stages, and is characterised by a slow precise adap-
tive response that develops over a period of days to several
weeks. In the initial stage pathogen-specific cell surface
receptors are used to recognise the invading microorganisms,
triggering the proliferation and differentiation of large copies
of pathogen-specific effector cells as part of the primary im-
mune response. Following pathogen elimination a proportion
of lymphocytes persist in the body, retaining immunological
memory that can be elicited through a faster secondary im-
mune response to eliminate the same pathogen in the event
of subsequent infections (Bonilla & Oettgen, 2010; Parham,
2009). Occasionally, in-borne errors in immune function oc-
cur, leading to the development of immune disorders includ-
ing asthma, Crohn’s disease (inflammatory bowel disease),
inflammatory arthritis, and autoimmune diseases such as
polyglandular syndrome and aspects of diabetes that result
from the immune system attacking host cells (Dessein, Cha-
maillard, & Danese, 2008; Finn & Bigby, 2009; Kim, DeKruyff,
& Umetsu, 2010; Mizuno, 2006; Obermayer-Straub, Strassburg,
& Manns, 2000; Sly & Holt, 2011; Van Heel, McGovern, & Jewell,
2001). In rare instances severe combined immunodeficiency
(SCID) can occur, which represents a group of sometimes fatalcongenital disorders characterised by little or no immune re-
sponse (Pearson, Greiner, & Shultz, 2008).
Multiple factors such as genetic predisposition, dietary in-
take, and stress, influence human immune function (Gleeson,
2005; Hughes, 1999; Ibs & Rink, 2003; Lomax & Calder, 2009;
O’Leary, 1990; Plat & Mensink, 2005; Webster Marketon & Gla-
ser, 2008). To preserve optimal immune function, plant food
supplements (PFS) have in recent years been increasingly
consumed (Canter & Ernst, 2004; Cassileth, Heitzer, & Wesa,
2009). While terms such as PFS, Botanicals, Nutraceuticals,
Functional Foods, Pharmafoods and others are sometimes
used interchangeably, the Directive 2002/46/EC of the Euro-
pean Parliament and of the Council defines food supplements
(FS) as ‘‘the foodstuffs for which the purpose is to supplement
the normal diet and that are concentrated sources of nutri-
ents or other substances with a nutritional or physiological
effect, alone or in combination, marketed in dose form,
namely forms such as capsules, pastilles, tablets, pills and
other similar forms, sachets of powder, ampoules of liquids,
drop dispensing bottles, and other similar forms of liquids
and powders designed to be taken in measured small unit
quantities. Plant Food Supplements (PFS) is a type of food
supplement (FS) in which botanicals preparations are the
main ingredients’’ (European Commission., 2002). From a reg-
ulatory perspective PFS are assimilated to foodstuff, and the
benefit health claims allowed in the commercialisation of
these products should exclude medical claims such as the
prevention, diagnosis and treatment of a recognised patho-
logical state. It is clear however that from the view-point of
consumers, improved regulatory and procedural frameworks
regarding health claims in general are still required given
existing knowledge, perceptions, attitudes, beliefs and behav-
iour (Pothoulaki & Chryssochoidis, 2009).This situation clearly
requires very careful definition of the population assessed in
clinical trials of PFS as well as the methods to be used in the
clinical evaluation of the benefits related to the use of PFS,
thus motivating this review. While a range of methodologies
exist to evaluate the claimed benefits of PFS on immune func-
tion, critical review of the underlying supporting data and the
relevance and utility of each method remains sparse. A major
challenge in assessing PFS’ benefits in the area of the immune
system is also posed by the vast complexity of this system.
In this review we examined data contained in peer-
reviewed publications of clinical trials involving human subjects
and assessed, primarily, the methodologies used to character-
ise the beneficial claims and effects of PFS on the human
body. A concise summary of this work is illustrated in Fig. 1.
Data for the review was sourced from the NCBI PubMed data-
base and included studies published between January 1990
and July 2011. In order to provide the broadest possible unbi-
ased overview of this area, data generated by non-random-
ised and / or controlled trials was also considered in order
to allow for the limitations of this data to be discussed. Bio-
chemical methods which assess immune function-related
Fig. 1 – Schematic summary of the research strategy and key outcomes described in this review.
Fig. 2 – Illustration of the literature search performed to identify suitable studies for inclusion.
1556 J O U R N A L O F F U N C T I O N A L F O O D S 5 ( 2 0 1 3 ) 1 5 5 4 –1 5 6 5biomarkers, and clinical tools and methods were both consid-
ered in the review. Based on our findings recommendations
for future research strategies are proposed, together with
guidelines that may assist in harmonising methodologies
used to determine the effects and benefit claims of plant food
supplements on immune function.
2. Literature search and study design
characteristics
The literature search interrogated immune function terms in-
cluded in the article title, abstract, keywords and MeSH terms
crossed with plant names and synonyms from the EuroFIR
database, resulting in the identification of 2562 studies ofpotential relevance to this review (Kiely et al., 2010). The re-
sults of the literature search are summarised in Fig. 2. Based
on the number of studies identified per plant species, the 10
plants most extensively studied for their effects on the im-
mune system were prioritised as reported below. In total
these plants were represented in 292 (11%) of the 2562 poten-
tially relevant studies. In order to be selected for further anal-
ysis, studies had to (i) primarily concern the clinical
evaluation of PFS, (ii) include the evaluation of beneficial ef-
fects of PFS on biomarkers of the immune system, (iii) be pub-
lished in the English Language, (iv) be representative of the
most commonly studied plant ingredients within PFS. All
studies that met these inclusion criteria and related to the
most extensively studied plants were further screened by title
J O U R N A L O F F U N C T I O N A L F O O D S 5 ( 2 0 1 3 ) 1 5 5 4 –1 5 6 5 1557and abstract for eligibility, resulting in 35 studies; the full arti-
cle of each study was subsequently retrieved for detailed
examination prior to selecting the final subset of studies for
extraction. Full article reviews were not possible for 7 articles
published in a language other than English, 4 articles were not
available from source, while a further 6 did not meet the cri-
teria for PFS. A total of 18 articles were eventually included in
the final data extraction set. In order of prevalence 8 of these
were based on double-blind randomised controlled trials
(Alvarez-Cuesta et al., 2005; Bergendiova, Tibenska, & Majtan,
2011; Bobovcak, Kuniakova, Gabriz, & Majtan, 2010; Briviba
et al., 2004; Rowe, Nantz, Bukowski, & Percival, 2007; Savolai-
nen, Jacobsen, & Valovirta, 2006; Savolainen et al., 2007; Tang
et al., 2009); 7 trials were conducted without placebo and/or
randomisation assignment (Barak, Birkenfeld, Halperin, &
Kalickman, 2002; Beltran-Debon et al., 2010; Calabrese et al.,
2000; Markovits, Ben Amotz, & Levy, 2009; Myers et al., 2010;
See, Mason, & Roshan, 2002; Watzl, Bub, Brandstetter, & Rec-
hkemmer, 1999); and the remainder were based on studies
of the following designs: a double-blind randomised con-
trolled cross-over trial (Riso et al., 2006), a randomised con-
trolled trial (Karlsen et al., 2010), and a randomised
controlled cross-over trial (Wood, Garg, Powell, & Gibson,
2008). Though the study inclusion criteria was as broad as
possible and criteria did not exclude specific trial designs,
not all trial designs were encountered in the final 18 selected
studies. The overall quality of study design, as assessed by a
methodological quality score was found to vary widely, with
3 being the highest and 0 the lowest score recorded. Not sur-
prisingly, the lowest scoring studies generally reflected those
without placebo and/or randomisation assignment. Overall
the majority of studies were assessed to be of moderate to
high quality (see Supplementary Table 1). Most studies incor-
porated the use of a placebo as the baseline comparator for
establishing efficacy while 5 employed baseline values. In a
single study a well-established reference supplement was
employed against which test PFS were compared (see Supple-
mentary Table 1). In total 523 participants were enroled across
the 18 studies with the smallest study containing 8 partici-
pants and the largest containing 62 (Karlsen et al., 2010;
Markovits et al., 2009).
3. Plant food supplements investigated in
review
The potential studies identified in database searches were
screened and ranked based on the plant active ingredient,
to identify the plants with the highest number of published
reports. The 10 most commonly studied PFS claimed to im-
prove or enhance immune function identified in this study
were: Andrographis paniculata (Green Chirayta) (Calabrese
et al., 2000; See et al., 2002), Camellia sinensis (Tea) (Myers
et al., 2010; Rowe et al., 2007), Corylus avellana (Common Hazel)
(Savolainen et al., 2006; Savolainen et al., 2007), Garcinia man-
gostana (Purple Mangosteen) (Tang et al., 2009), Hibiscus sabda-
riffa (Roselle) (Beltran-Debon et al., 2010), Lycopersicon
esculentum (Tomato) (Briviba et al., 2004; Markovits et al.,
2009; Riso et al., 2006; Watzl et al., 1999; Wood et al., 2008),
Olea europaea (Olive) (Alvarez-Cuesta et al., 2005), Pleurotusostreatus (Oyster Mushroom) (Bergendiova et al., 2011; Bobovcak
et al., 2010), Sambucus nigra (Elderberry) (Barak et al., 2002), and
Vaccinium myrtillus (Bilberry) (Karlsen et al., 2010). The wide-
spread consumption of several PFS obtained from these
plants for enhancing immune function is well documented
(Cassileth et al., 2009). PFS in the reviewed studies were
administered either orally in capsule form, sublingually, or
parenterally through injections. In the majority of trials
(twelve in total), PFS formulations were sourced from com-
mercial manufacturers and suppliers; in six trials the manu-
facturing source of the formulation was not stipulated. The
majority of trials investigated single formulation supple-
ments in capsule, liquid, or injectable form, most of which
were sourced from commercial suppliers. In a minority of
studies supplement formulations included additional PFS or
minerals as part of the treatment regime. None of the addi-
tional constituents were reported to have a significant effect
on the observed clinical outcomes, however in a number of
studies such effects were not directly investigated and this
potential could not be assessed or ruled out.
4. Supplementation effects and adverse event
reporting
The inclusion criteria for the study population and the clinical
outcomes being assessed varied widely across studies (Sup-
plementary Table 1); these included common cold and flu, se-
vere viral infection, immunomodulated symptoms that
included allergy, and systemic inflammation. More appropri-
ately considering the definition of PFS, the majority of studies
(eleven out of the eighteen studies identified) investigated the
direct effects of PFS in non-symptomatic cohorts, using ge-
netic, protein and cellular biomarkers commonly associated
with immune function as the underlying end-point indicator.
For this review the definition of biomarker was defined
according to the Biomarkers Definitions Working Group,
whereby a biomarker is ‘‘a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacological re-
sponses to a therapeutic intervention’’ (Biomarkers Defini-
tions Working Group. 2001). The key effects observed on
immune function following PFS are summarised in Supple-
mentary Table 2. In order to limit these observations to stud-
ies that inherently provide a higher level of confidence,
studies in the table represent those based solely on random-
ised controlled trials. Whilst significant effects were observed
in all of these studies the scope and magnitude of these ef-
fects varied considerably. For example supplementation with
G. mangostana resulted in a small but statistically significant
increase over baseline in double positive (DP) T cell frequency
(0.28%) compared to a decrease of 0.18% in the control group
(p = 0.038). In contrast a relatively large effect was observed
for L. esculentum, the use of which resulted in a significant de-
crease (34.4%, p < 0.05) compared to placebo in tumour necro-
sis factor (TNF) alpha production, which is an important
immune cytokine involved in systemic inflammation (Tang
et al., 2009). Supplementation with this PFS was also observed
to induce significant decreases (20%, p = 0.009) in IL-4 produc-
tion levels, which is a key regulator involved in adaptive
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PFS on other specific immune functions were also observed.
Overall, the majority of studies did not report on the nat-
ure or prevalence of adverse events observed during or after
PFS exposure. In instances where these events were reported
symptoms included allergic reaction, fatigue, headache, pluri-
tis or rash, loose stools or diarrhoea, nausea, metallic taste,
bitter taste, decreased or no taste, dry tongue, decreased sex
drive, eyes sensitive to light, decreased short term memory,
dizziness, heartburn, tender lymph nodes, and lymphade-
nopathy in the case of A. paniculata supplementation; local-
ised skin reactions following O. europaea immunotherapy;
and diarrhoea, mild skin rash, gastric upset, dizziness, skin
rash, and constipation in the case of C. sinensis supplementa-
tion. Interestingly a number of C. sinensis-related symptoms
were also noted in the placebo group (Alvarez-Cuesta et al.,
2005; Calabrese et al., 2000; Myers et al., 2010; Rowe et al.,
2007). No adverse events were observed amongst participants
receiving PFS derived from G. mangostana, L. esculentum, or P.
ostreatus (Bergendiova et al., 2011; Briviba et al., 2004; Tang
et al., 2009). Treatment duration was observed to vary widely,
from regimes lasting a month or shorter (Beltran-Debon et al.,
2010; Briviba et al., 2004; Karlsen et al., 2010; Markovits et al.,
2009; Riso et al., 2006; Tang et al., 2009; Wood et al., 2008) to
longer-term regimes lasting up to two years (Savolainen
et al., 2006; Savolainen et al., 2007).
5. Methods used to assess the immunological
benefits of PFS
A wide range of methods were identified that are used to as-
sess the potential benefits of PFS on immune function, and
these could be clearly categorised into bioanalytical ap-
proaches and non-invasive clinical tools and rating scales
(summarised in Table 1). In the case of well-designed trials
based solely on a randomised, blinded, controlled design,
the selected methods could confirm at statistically significant
levels, the claimed PFS benefit (s) on specific outcomes of im-
mune function. It is interesting and relevant to note that in
the cases where such claims could not be supported by the
methods used, the respective groups had chosen to employ
an open study design (Barak et al., 2002; Markovits et al.,
2009). While the number of studies included in this review
is limited in size, this observation raises the question about
the extent to which failure to observe a therapeutic effect in
open studies may be due to limitations in study design rather
than a true lack of PFS efficacy. Clearer certainty could
potentially be achieved by choosing to employ a study design
based on a more robust randomised, blinded, controlled
approach. The most cited bioanalytical method was based
on immunoassay technology, with the immunoassay en-
zyme-linked immunosorbent assay (ELISA) representing the
most popular approach (Engvall & Perlmann, 1971; Riso
et al., 2006; Rowe et al., 2007; See et al., 2002; Watzl et al.,
1999; Wood et al., 2008). In the studies reviewed, this method
was often employed for measuring circulating levels of a
broad range of cytokines (e.g. TNF-alpha and multiple
interleukins) and soluble cytokine receptors (e.g. TNF receptor
type-1) (Table 1).Another frequently cited method was flow cytometry,
which was mainly employed to quantitatively measure
changes to immune function-related cell numbers following
PFS supplementation. This typically involved determining
absolute counts of cells associated with innate response such
as neutrophils, monocytes, macrophages and cytokines, and
adaptive immune response processes e.g. T and B lymphoct-
yes (Bergendiova et al., 2011; Bobovcak et al., 2010; Calabrese
et al., 2000; Myers et al., 2010; Rowe et al., 2007; Tang et al.,
2009). In a number of studies the percentage contribution or
ratio of each subclass to the total cell count was also used
as the primary measure (Table 1) (Rowe et al., 2007). The
method has also been adapted to measure cytokines (e.g.
TNF-alpha and interleukins) and soluble cytokine receptors
(e.g. TNF receptor type-1), as well as measuring the phago-
cytic activity of granulocytes and monocytes (Table 1). Varia-
tions to conventional flow cytometry included the upstream
integration of solid phase immunoassay-based protein arrays
which employ spectrally encoded antibody-conjugated beads
designed for use in single ormultiplexed assays (Beltran-Debon
et al., 2010; Karlsen et al., 2007; Karlsen et al., 2010). The assay
is performed in 96-well plate format and is read using flow
cytometry-based technology that provides levels of quantita-
tion and sensitivity comparable to ELISA. Biomarkers typi-
cally investigated through this approach include
interleukins (e.g. Il-6 and Il-8) and themonocyte chemoattrac-
tant protein-1 (MCP-1).
The quantitative Real-Time polymerase chain reaction
method (qRT-PCR) was another commonly employed tech-
nique, which is used to amplify and facilitate the detection
of constitutive mRNA and/or DNA species representing
immune biomarkers or pathogenic organisms of interest
(Calabrese et al., 2000; Mullis et al., 1986; Savolainen et al.,
2006; Savolainen et al., 2007). The method was found to be
effective for quantifying relative interleukin levels (e.g. Il-4,
Il-5, and Il-10), and levels of interferon (e.g. IFN-gamma) and
related growth factors (e.g. TGF-beta) (Savolainen et al.,
2006; Savolainen et al., 2007). The method was also capable
of reliably quantifying HIV-1 copy numbers (Calabrese et al.,
2000). Equally common were microscopy-based methods
which are used to visually quantitate immune biomarkers
(for example lymphocyte levels), typically through the use
of haemocytometer counts (Bobovcak et al., 2010; Tang
et al., 2009). The least cited method was nephelometry, which
exploits the properties of light-scatter emitted by turbid sam-
ples to analyse macromolecules, for example total serum
immunoglobulins (DeGrella et al., 1985; Tang et al., 2009).
Non-invasive methods included direct skin reaction tests
measured by planimetry using computerised scanners, and
the use of clinical rating scales for quality of life measure-
ments, for example non-hayfever symptoms, nasal symp-
toms, eye symptoms, and overall quality of life following
the intake of PFS (Alvarez-Cuesta et al., 2005; Savolainen
et al., 2006; Savolainen et al., 2007).
6. Discussion
The focus of this review was to assess the current methodol-
ogies used to characterise the benefit claims of PFS on human
Table 1 – Current methods used to assess the potential benefits of plant food supplements on immune function. Key biomarkers and clinical outcomes are listed
according to the method used. Common advantages and disadvantages associated with the use of each method are also described.
Method References Immune biomarkers/clinical
variables measured
Advantages Disadvantages
Immunoassay
(Direct ELISA)
See et al. (2002)* TNF-alpha, and soluble TNF receptor
type-I
Fast, minimal preparation and can be
performed on whole blood, medium
sample throughput, reasonably low
sample volume requirements, no
secondary antibody cross reactivity
Enzyme labelling may affect primary
antibody immunoreactivity; minimal
signal amplification; relatively
expensive approach which requires
primary antibody labelling for each
specific ELISA assay
(Sandwich ELISA) Rowe et al. (2007) IFN-gamma levels from PBMC culture
supernatants
Fast, can be performed on whole blood,
medium sample throughput, reasonably
low protein and sample volume
requirements, good sensitivity and
selectivity, circumvents creation of
enzyme-linked antibodies for every
antigen of interest
Potential for cross-reactivity with
secondary antibody, longer incubation
and processing step required
(Sandwich ELISA) Tang et al. (2009) Serum interleukins (IL-1alpha, IL-1beta,
and IL-2)
Fast, can be performed on whole blood,
medium sample throughput, reasonably
low protein and sample volume
requirements, good sensitivity and
selectivity, circumvents creation of
enzyme-linked antibodies for every
antigen of interest
Potential for cross-reactivity with
secondary antibody, longer incubation
and processing step required
(Direct ELISA) Wood et al. (2008) Neutrophil elastase Fast, minimal preparation and can be
performed on whole blood, medium
sample throughput, reasonably low
sample volume requirements, no
secondary antibody cross reactivity
Enzyme labelling may affect primary
antibody immunoreactivity; minimal
signal amplification; relatively
expensive approach which requires
primary antibody labelling for each
specific ELISA assay
(Direct ELISA) Watzl et al. (1999) Lymphocyte and IL-2/IL-4 production Fast, minimal preparation and can be
performed on whole blood, medium
sample throughput, reasonably low
sample volume requirements, no
secondary antibody cross reactivity,
measures cell proliferation by
quantitating 5-bromo-2-deoxyuridine
incorporated into newly synthesized cell
DNA; good sensitivity
-
(Sandwich ELISA) Barak et al. (2002)* Cytokine production (IL-1b, TNFa, IL-6, IL-
8, IL-10)
Fast, can be performed on whole blood,
medium sample throughput, reasonably
low protein and sample volume
requirements, good sensitivity and
selectivity, circumvents creation of
enzyme-linked antibodies for every
antigen of interest
Potential for cross-reactivity with
secondary antibody, longer incubation
and processing step required
JO
U
R
N
A
L
O
F
F
U
N
C
T
I
O
N
A
L
F
O
O
D
S
5
(2
0
1
3
)
1
5
5
4
–
1
5
6
5
1
5
5
9
(Sandwich ELISA) Karlsen et al. (2010) IL-1beta, IL-1alpha, IL-1 receptor
antagonist (IL-1Ra), IL-2, IL-2R IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-
17, TNF-alpha, interferon (IFN)-alpha,
IFN-gamma, granolyte/macrophage
colony-stimulating factor (GM-CSF),
macrophage inflammatory protein 1-
alpha and 1-beta, immunoprotein (IP)-10,
monocyte chemoattractant protein-1
(MCP-1), monokine induced by IFN-
gamma (MIG), eotaxin and regulated
upon activation
Fast, can be performed on whole blood,
medium sample throughput, reasonably
low protein and sample volume
requirements, good sensitivity and
selectivity, circumvents creation of
enzyme-linked antibodies for every
antigen of interest
Potential for cross-reactivity with
secondary antibody, longer incubation
and processing step required
Flow cytometry Calabrese et al. (2000)
and Myers et al. (2010)*
Normal T cell expressed and secreted
(RANTES) measured in heparin plasma
Relatively fast, medium to high sample
throughput, reasonably low protein and
sample volume requirements
Moderate to high equipment and
reagent costs
Myers et al. (2010)* Granulocyte and monocyte phagocytic
activity
Relatively fast, medium to high sample
throughput, reasonably low protein and
sample volume requirements
Moderate to high equipment and
reagent costs
Rowe et al. (2007) Ratio of alpha-beta and gamma-delta T
cells in PBMC suspensions
Relatively fast, medium to high sample
throughput, reasonably low protein and
sample volume requirements
Moderate to high equipment and
reagent costs
Tang et al. (2009) Gamma-delta-T cells (CD3+, CD4,
CD8), T-helper cells (CD3+, CD4+, CD8),
cytotoxic T cells (CD3+, CD4, CD8+),
CD4/CD8 double-positive T cells (CD3+,
CD4+, CD8+), and Th to Tc cell ratio (Th/
Tc).
Relatively fast, medium to high sample
throughput, reasonably low protein and
sample volume requirements
Moderate to high equipment and
reagent costs
(Bead-array flow cytometry) Beltran-Debon et al.
(2010)*
IL-6, IL-8, and MCP-1 measured in
supernatants and plasma aliquots
Cytometric bead-based assay – multiplex
capable, relatively fast, high sample
throughput
Moderate to high equipment and
reagent costs
Bobovcak et al. (2010) Leucocyte and lymphocyte counts; NK-
cell activity
Relatively fast, medium sample
throughput
Moderate to high equipment and
reagent costs
Bergendiova et al. (2011) Phagocytosis and NK cell count Relatively fast, medium sample
throughput
Moderate to high equipment and
reagent costs
Riso et al. (2006) IFN-gamma and TNF-alpha production Relatively fast, medium sample
throughput
Moderate to high equipment and
reagent costs
Microscopy Tang et al. (2009) Lymphocyte counts Cheap, accurate, visual Labour intensive, not readily amenable
to high-throughput applications
Haematology analyser Myers et al. (2010)* Total white blood cell and lymphocyte
numbers as a percentage of total blood
cells
Automated, relatively fast, multiple tests,
medium sample throughput; low C.V.
Moderate equipment cost
(continued on next page)
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Table 1 – Continued
Method References Immune biomarkers/clinical
variables measured
Advantages Disadvantages
Watzl et al. (1999)* Total leucocyte numbers Automated, relatively fast, multipl tests,
medium sample throughput; low C .
Moderate equipment cost
Nephelometry Tang et al. (2009) Serum total immunoglobulins (Igs) (IgG,
IgA, and IgM), complement components
(C3 and C4), and CRP
Quick, automated, multiple tests Moderate equipment cost
Conventional/quantitative
Real-Time PCR
Calabrese et al. (2000) HIV-1 RNA Fast, sensitive, high sample throug put,
low limit of detection, can be multi lexed
May require multiple sample
preparation steps, moderate equipment
and reagent costs
Savolainen et al. (2006) Quantitation of IL-4, IL-5, IL-10, IFN-
gamma and TGF-beta
Fast, sensitive, high sample throug put,
low limit of detection, can be multi lexed
May require multiple sample
preparation steps, moderate equipment
and reagent costs
Savolainen et al. (2007) Quantitation of IL-18, signalling
lymphocytic activation molecule, GATA-
3, IL-10, and TGF-beta
Fast, sensitive, high sample throug put,
low limit of detection, can be multi lexed
May require multiple sample
preparation steps, moderate equipment
and reagent costs
Gamma radiation measurement See et al. (2002) Natural killer cell activity against 51-
chromium labelled MOLT-4 acute
lymphoblastic leukaemia cells
Sensitive Use of radiolabels
Diary cards Rowe et al. (2007) Cold and flu symptoms (runny nose,
congested or stuffy nose, headache,
cough, sore throat, fever, nausea/
vomiting, and diarrhoea)
– Subjective
Alvarez-Cuesta et al.
(2005)
Pollen count, symptom and medication
scores
– Subjective
Bergendiova et al. (2011) Nasal congestion, runny nose, sore
throat, sneezing, and cough
– Subjective
Planimetry Savolainen et al. (2006)
and Savolainen et al.
(2007)
Skin wheal following skin prick test Fast, objective, visual –
Alvarez-Cuesta et al.
(2005)
Skin wheal following skin prick test Fast, objective, visual –
* Studies based on a non-randomised controlled trial design. Inclusion of these studies serves to highlight overlaps that exist in method selection nd use across studies in the field. Priority should
however be placed on the suitability of methods employed in randomised controlled studies.
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viewed publications of human clinical trials using the most
widely researched botanical ingredients for this indication.
A total of 18 trials were reviewed, and in order to provide a
comprehensive overview of the state-of the-art, those with-
out placebo controls or randomisation were also considered
with restrictions. Trials of this nature accounted for more
than a third of those identified, thereby representing a nota-
ble proportion of studies performed in this area. The value
of uncontrolled trials is however significantly diminished by
a number of inherent limitations and biases. These include
selection bias and the risk of knowledge of which interven-
tion was received, which may inevitably impact on study out-
come and outcome measurements. This may be particularly
the case when assessing subjective outcomes, such as those
based on methods for self-reporting measures. The seven
uncontrolled or non-randomised trials included in this review
may thus only be considered exploratory and hypothesis-
generating, with their usefulness limited to gaining insights
into the potential effects or benefits of plant food supplemen-
tation in specific populations and the ability of certain exper-
imental methods to assess these outcomes. Less confidence
must therefore be placed on the findings of these studies,
compared to those based on randomised, blinded, controlled
trials that represent a more robust study design. While the
current review was limited to the most commonly studied
PFS, the number of studies identified allowed us to obtain a
non-biased sample of the methods most commonly used in
the evaluation of PFS benefits on the immune system. It
should be noted that this review was non-systematic in nat-
ure and that a number of relevant methods may have been
neglected by the exclusion of papers not related to the most
commonly used PFS. Furthermore data from unpublished tri-
als, such as that found in clinical trials registries, and trials
conducted in languages other than English were not included.
Overall the general quality of studies reviewed varied from
those of high quality to those that can be considered rela-
tively poor; for studies of moderate to high quality sound con-
clusions could be drawn about the appropriateness and
relative performance of the outcome assessment methods
used. For those deemed to be of low design quality, or in in-
stances where critical information such as detailed demo-
graphic data was missing, it was not possible to fully
establish the relevance of the conclusions outlined in the
study. Quite appropriately considering the regulatory status
of PFS, the majority of studies employed healthy or non-
pathological populations to examine the effect of PFS on bio-
markers of immune disease function. Due to their regulatory
status, PFS should not claim medical properties, and there-
fore their beneficial effects may be best demonstrated in
healthy populations. Studies of healthy populations within
the sample showed a higher level of quality with over 70%
of reports presenting a quality score of 2 or higher, while al-
most 60% of studies of diseased populations had a score of
1 or less. Considering that the ratings scale used in this
assessment reflects the quality of study design as well as
the completeness of the reporting, this observation may indi-
cate that the study of healthy populations is inherently better
suited to PFS. Besides being out of the regulatory scope of PFS
definition, the study of PFS in diseased populations iscomplicated by issues such as co-medication, adverse event
reporting and ethical considerations around the use of a
non-medicinal issued for a medical condition.
Diverse study designs were employed across the trials, the
majority of which were based on a double-blind randomised
controlled design. Trial designs did not appear to influence
the outcome of PFS treatment effects; in all but two studies
significant effects of PFS on immune function were observed.
In both these non-significant studies the sample size was rel-
atively small; in one study a sample total of 12 healthy sub-
jects was used to assess the immune-enhancing effects
against baseline measurements of preparations of S. nigra;
in the second study 8 clinically obese subjects and 8 healthy
age and gender-matched controls were used to investigate
the effects of L. esculentum supplementation. Given the rela-
tively small sizes of these cohorts the possibility exists that
the samples were underpowered to detect any significant ef-
fects that might have been present following treatment. As
highlighted in the results, and summarised in Supplementary
Table 2, a number of these effects could be deemed relatively
small. Both studies were thus rated low in terms of sample
size quality, with only two other studies having similarly
sized cohorts of 10 and 13 participants; on average 28 partic-
ipants were recruited across each of the 18 studies. In addi-
tion to meeting minimum requirements for sample size, the
routine inclusion of healthy subjects should also be consid-
ered. The primary benefit derived from this is a better defini-
tion of the limits of normal with respect to biochemical
markers of interest, which in turn can be used to more pre-
cisely delineate the physiological effects of PFS in patients.
The prevalence or nature of adverse events (or lack there-
of) observed during or after PFS exposure was not reported for
the majority of studies. Adverse events nevertheless repre-
sent a major concern associated with the use of PFS, where
supplement-drug interactions for example may be exacer-
bated under certain physiological states, or may interfere
with prescription medications (Cassileth et al., 2009). Such
interactions are a particularly important consideration for
PFS used to enhance immune function where, due to the
complexity of the immune system, increasing certain constit-
uents may be beneficial, whilst for other constituents this
could have the opposite effect (Cassileth et al., 2009). Individ-
uals with autoimmune diseases for example, or those receiv-
ing immunosuppression medications could thus be
predisposed to complications and unwanted clinical effects
due to PFS-induced increases in immune function, and the
reporting of adverse events during trials designed to assess
PFS benefits on immune function would therefore be useful
for assessing a priori the risk–benefits of such treatment.
A broad range of bioanalytical methods were identified
that are suited to assessing the potential benefits of PFS on
immune function. In order to provide the highest possible
confidence in this selection, distinction has been made be-
tween those methods employed in randomised controlled tri-
als and those used in open trials (see Table 1). Methods
included more common approaches based on immunoassay
technology, flow cytometry, PCR, and microscopy, and less
frequently used methods such as nephelometry. Immunoas-
says proved to be the most popular method with ELISA being
found to be particularly widespread. Primary advantages of
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and the wide range of biomarkers that can typically be de-
tected using this technology. This included qualitative and
quantitative detection of circulating white blood cells, for
example monocytes and lymphocytes, levels of total immu-
noglobulins and immunoglobulin subclasses, cytokines and
cytokine receptors, and phagocytosis and natural killer-cell
activity. Statistically significant changes to the production
and activity of these biomarkers were readily identified
throughout different study groups undergoing treatment with
a range of PFS. This capability was also observed in studies
employing flow cytometry as a means of assessing benefit,
for which the technology proved efficient at determining
absolute counts of cells associated with innate response.
These included neutrophils, monocytes, macrophages and
cytokines, and lymphoctyes. Flow cytometry was found to
be highly sensitive and amenable to medium-throughput
use under a clinical setting. Microscopy-based methods were
also identified. These were used to visually quantitate im-
mune biomarkers, for example circulating lymphocytes; how-
ever this approach is relatively labour intensive and may
generally not be amenable to processing large sample num-
bers in an economic manner. The use of more recent technol-
ogies such as qRT-PCR was not widespread, despite the
sensitivity and diverse application potential of such ap-
proaches. In the case of qRT-PCR the technology is also ame-
nable to high-throughput use although the associated costs
can be high. Generally, the use of other relatively recent tech-
nologies such microarrays and mass spectrometry was not
observed in any of the studies included in this review. Whilst
the cost of implementing such technologies may be consid-
ered high, their sensitivity and throughput often translates
to markedly lower costs per data point, in the process en-
abling a more comprehensive understanding of cause-and-
effect to be gained. Such technologies may therefore prove
useful in future to improving our understanding and valida-
tion of PFS benefit claims. In the case of four studies insuffi-
cient detail was given regarding the methods used to assess
PFS benefit – in each of these cases the methods were refer-
enced. Interestingly, the bioanalytical methods used to assess
PFS activity seemed to vary slightly depending on the nature
of the population studied, with immunoassay and flow
cytometry methods being more represented in the study of
healthy populations, and PCR and planimetry being more rep-
resented in the study of diseased populations. While comput-
erised planimetry is intrinsically related to the measure of
allergic reactions in sensitised individuals, the greater use of
PCR in the study of diseased populations could be a spurious
observation due to the limited number of studies of diseased
populations included in this review. In contrast to bioanalyti-
cal methods, a number of studies employed clinical rating
scales as the primary outcome measure for assessing benefit.
These predominantly included the use of diaries and score
cards designed to record symptomology, for example the
prevalence of cold symptoms, during treatment. Very few
studies employed the use of both bioanalytical and clinical
approaches to simultaneously assess benefit. The use of study
designs that incorporate both approaches would providestronger support for validating claims by demonstrating cor-
relation across multiple assessment domains.
In order to obtain a broad overview of the methods used to
assess the effects of PFS on immune function, this review
chose to include studies that are not based on a randomised
controlled design. While such studies are widely employed,
they are considered exploratory and of relatively low confi-
dence. To gain a broader overview of the field the inclusion
of methods from studies beyond the top 10 PFS may have
proved useful. Few studies provided details about the valida-
tion status of their methods and the authors acknowledge
that the inclusion of data from poorly validated or un-
validated methods which can affect the reliability and repro-
ducibility of end-point outcome measurements represents a
limitation. This shortfall can be circumvented by limiting
studies to those that employ methods that have clearly been
validated in-house, thereby increasing the likelihood that sig-
nificant findings can be confirmed. Lastly, although statistical
power estimates were not provided for a number of studies,
the sample sizes described appeared to be relatively low in
some cases to sufficiently detect the benefit effects claimed
from PFS use. By limiting included studies to those that pos-
sess adequate sample power the findings and conclusions
drawn from such work could be made more robust.
7. Conclusions
At total of 9 distinct methodswere identified in this review for
assessing the potential benefits of PFS on human immune
function. Despite wide differences in the underlying principle
of the approaches used, the performance of each was found
to be suited to analysing biomarkers, or clinical symptoms,
associated with the effects of PFS on the immune function
of healthy as well as diseased individuals. The appropriate-
ness of each method was generally limited to assessing spe-
cific biomarkers or symptoms, and patient sample size and
the overall quality of the study design appeared to influence
trial outcome. The use of additional modern analytical meth-
ods, combined with the use of adequately powered cohorts
and improvements in outcomes reporting would contribute
greatly towards advancing existing knowledge and under-
standing of the benefits of PFS on human immune function.
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